Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378196 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00378196: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT00378196 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00378196, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378196
The ClinicalTrials.gov registry entry for NCT00378196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00378196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00378196 about?
NCT00378196 is a clinical study titled "Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial". This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in th...
What is the current status of trial NCT00378196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2006-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00378196?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00378196?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.